Tech Company Financing Transactions
ViaCyte Funding Round
ViaCyte closed a $5.4 million Series C financing round on 8/8/2014. Backers included private investors.
Transaction Overview
Company Name
Announced On
8/8/2014
Transaction Type
Venture Equity
Amount
$5,400,000
Round
Series C
Investors
Proceeds Purpose
The Company will use the funds to pursue clinical development of its VC-01� product candidate. ViaCyte also recently announced the submission of an Investigational New Drug application and a Medical Device Master File to the U.S. Food and Drug Administration seeking permission to begin clinical evaluation of the product candidate.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
3550 General Atomics Ct.
San Diego, CA 92121
USA
San Diego, CA 92121
USA
Phone
Website
Email Address
Overview
ViaCyte is a preclinical therapeutic company focused on diabetes. Our therapy is based on pancreatic beta cell progenitors (Pro-Islet) derived from human pluripotent stem cells. These cells are implanted using a durable and retrievable encapsulation device.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Michael Yang
Chief Financial Officer
Brittany Bradrick
Chief Medical Officer
Howard Foyt
Chief Scientific Officer
Kevin D'Amour
Chief Technical Officer
Steve White
Vice President
Manasi Jaiman
VP - Finance
Anne Sandan
VP - General Counsel
Liz Bui
VP - Regulatory Affairs
Steve Kradjian
Browse more venture capital transactions:
Prev: 8/7/2014: Lifetime Oil venture capital transaction
Next: 8/8/2014: Aegis Mobility venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs